Evidence map›Paper›PMID 37505393›Full record

ArticleDermatology and therapy2023

Patient Experience of Lichen Planus: A Qualitative Exploration of Signs, Symptoms, and Health-Related Quality of Life Impacts.

Aoife Mahon-Smith, Molly Clifford, Anjali Batish, Rosie Sharp, Charlotte Panter, Christel Naujoks, Eva Schruf, Nicolò Compagno, Santiago G Moreno

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Dermatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04300296 (A Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 mg Over 32 Weeks in Adult Patients With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies - PRELUDE), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04300296 phase2completednot on this map

A Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 mg Over 32 Weeks in Adult Patients With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies - PRELUDE

TypeinterventionalSponsorNovartis PharmaceuticalsRan2020 to 2022Enrolled111ConditionsLichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen PlanopilarisArmssecukinumab 300 mg Q4W, secukinumab 300 mg Q2W, Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Durability of Conventional Immunosuppressants in the Treatment of Oral Lichen Planus.The Journal of clinical and aesthetic dermatology · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Aoife Mahon-SmithPatient-Centered Outcomes, Adelphi Values Ltd, Bollington, Cheshire, UK. aoife.mahon-smith@adelphivalues.com.ORCID http://orcid.org/0000-0003-1167-7693
Molly CliffordPatient-Centered Outcomes, Adelphi Values Ltd, Bollington, Cheshire, UK.ORCID http://orcid.org/0000-0002-9707-465X
Anjali BatishPatient-Centered Outcomes, Adelphi Values Ltd, Bollington, Cheshire, UK.ORCID http://orcid.org/0000-0002-1008-9710
Rosie SharpPatient-Centered Outcomes, Adelphi Values Ltd, Bollington, Cheshire, UK.ORCID http://orcid.org/0000-0002-4111-4181
Charlotte PanterPatient-Centered Outcomes, Adelphi Values Ltd, Bollington, Cheshire, UK.ORCID http://orcid.org/0000-0001-7172-8937
Christel NaujoksNovartis Pharma AG, Basel, Switzerland.ORCID http://orcid.org/0000-0002-3799-6521
Eva SchrufNovartis Pharma GmbH, Nürnberg, Germany.ORCID http://orcid.org/0000-0002-1412-5141
Nicolò CompagnoNovartis Pharma AG, Basel, Switzerland.ORCID http://orcid.org/0000-0002-7590-4093
Santiago G MorenoNovartis Pharma AG, Basel, Switzerland.ORCID http://orcid.org/0000-0002-6341-7546
Adelphi Group (United Kingdom) · GBNovartis (Switzerland) · CHNovartis (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLichen planus (LP) is an inflammatory skin disorder that can present in various forms across the body, including lesions on the skin (cutaneous LP [CLP]), scalp (lichen planopilaris [LPP]), and mucosal regions (mucosal LP [MLP]). Qualitative exploration of the patient experience of LP, notably symptoms and impacts on health-related quality of life (HRQoL), is limited. A scarcity of research was also identified relating to emotional wellbeing impacts of CLP patients. Two qualitative studies were conducted with LP patients to address these gaps.

methodsStudy 1 consisted of exit interviews conducted with a subset of adult patients with MLP (n = 5), CLP (n = 4), and LPP (n = 4) enrolled in an LP clinical study in the United States (US) to explore the patient experience. Study 2 consisted of independent qualitative interviews conducted with adult CLP patients (n = 13) from the US and Germany to further explore impacts on emotional wellbeing.

resultsExit interviews found that itch , pain, and skin lesions were most frequently reported as signs/symptoms of LP. Itch and skin lesions were experienced across all LP subtypes, while pain was only reported by CLP and MLP patients. These signs/symptoms impacted HRQoL including emotional wellbeing (frustration, embarrassment), daily activities (oral hygiene, clothing options), social functioning (intimacy, social activities), and physical functioning (chewing/swallowing, opening/moving mouth). Impacts on activities of daily living (ADL) and physical functioning were mostly experienced by MLP patients. Independent qualitative interviews, which further explored impacts of CLP on patients' emotional wellbeing, identified frustration, worry, sadness, embarrassment, and depression as the most frequently experienced.

conclusionThe findings contribute to the literature by providing qualitative insights into signs/symptoms and HRQoL impacts of LP, from the adult patient perspective. The findings also highlight the importance of considering assessment of HRQoL impacts in future clinical LP research, particularly impacts on emotional wellbeing when selecting instruments for assessment of HRQoL in the CLP population.

trial registrationNCT04300296.

Indexed as

Clinical outcome assessmentsConcept elicitationDisease experienceExit interviewsHealth-related quality of lifeLichen planusPatient experiencePatient reported outcomesQualitative interviewsSigns and symptoms

Identifiers

PMID37505393
PMCPMC10442305
OpenAlexW4385331207

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.